Knockdown of Sema6D can down-regulate ERK, PI3K/AKT/mTOR signaling pathway-related protein expression and inhibit the proliferation, migration and invasion of gastric cancer cells, which is expected to be an effective target for gastric cancer drug development and has clinical research value. The gene discussed is AKT1; the disease is gastric cancer.